Back to Search
JESSICA LEE KARP DO
DO
Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician
NPI: 1023243698IndividualAccepts Medicare
Specialties, Licenses & Credentials
Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) PhysicianPrimary
Obstetrics & Gynecology — Urogynecology and Reconstructive Pelvic Surgery
Code: 207VF0040X
OS14382(FL)34.016853(OH)
Urogynecology and Reconstructive Pelvic Surgery (Urology) Physician
Urology — Urogynecology and Reconstructive Pelvic Surgery
Code: 2088F0040X
OS14382(FL)
Education
PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE
Class of 2009
Research & Publications (20)
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
PMID 19109557·Blood·2009
3-trial
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
PMID 17640728·Leuk Res·2008
3-trial
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
PMID 18483374·Clin Cancer Res·2008
3-trial
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
PMID 17671131·Clin Cancer Res·2007
3-trial
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
PMID 17562873·Blood·2007
3-trial
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
PMID 17882662·Cancer Invest·2007
6-review
Targeting the process of farynesylation for therapy of hematologic malignancies.
PMID 16305490·Curr Mol Med·2005
6-review
Trying to improve clinical outcome in AML: lessons from negative trials.
PMID 15863196·Leuk Res·2005
8-other
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
PMID 16322302·Clin Cancer Res·2005
3-trial
Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
PMID 16556050·Future Oncol·2005
6-review
Sanguinarine activates polycyclic aromatic hydrocarbon associated metabolic pathways in human oral keratinocytes and tissues.
PMID 15993743·Toxicol Lett·2005
8-other
Farnesyl transferase inhibition in hematologic malignancies.
PMID 16280111·J Natl Compr Canc Netw·2005
8-other
Adjunctive chemotherapeutic suppression of mutans streptococci in the setting of severe early childhood caries: an exploratory study.
PMID 19486465·J Public Health Dent·2009
8-other
Experimental evaluation of a simple lesion detection task with time-of-flight PET.
PMID 19098351·Phys Med Biol·2009
8-other
Psychiatric aspects of nonpsychiatric disorders in older adults.
PMID 19307855·Am J Geriatr Psychiatry·2009
8-other
The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization.
PMID 19472438·Am J Geriatr Psychiatry·2009
8-other
Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience.
PMID 19525463·J Nucl Med·2009
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 7740 WASHINGTON VILLAGE DR STE 160
CENTERVILLE, OH 45459 - Phone
- (937) 436-9825
Quick Facts
- NPI
- 1023243698
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 2
- Years in Practice
- 17
- Publications
- 20
Are you this provider?
Claim Your Profile